US Cancer Diagnostics Market Future Horizons and Growth Strategies: Supplier Shares by Tumor Marker, Country Segment Forecasts, Competitive Intelligence, Opportunities [Updated: 11082016] Prices from USD $9800
21 May 2017
Antibody
Complete report $9,800.nbsp; DataPack test volumes, sales forecasts, supplier shares $6,400.
VPG Market Research's new report is a strategic analysis of the major business opportunities emerging in the cancer diagnostics market during the next five years. The report examines trends in the US cancer diagnostics markets; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.
nbsp;
Rationale
The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.
Business Opportunities and Strategic Recommendations
Specific new product development opportunities with potentially
significant market appeal during the next five years.
Design criteria for new products.
Alternative market penetration strategies.
Potential market entry barriers and risks.
Cancer Diagnostic Testsmdash;Over 200 current and emerging assays including:
ACTH, AFP, Beta2 Microglobulin, CA 153/27.29, CA 199, CA 125, Calcitonin, Cathepsin, CEA,
Chromogranin, ColonSpecific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG,
Insulin, Interferons, Interleukins, Lymphocyte Subtyping, NeuronSpecific Enolase, Nucleolar,
Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone,
Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S100 Protein,
Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin,
Tissue Polypeptide Antigen, and others.
Market Segmentation Analysis
Sales and market shares of major suppliers,
by individual cancer diagnostic test.
Fiveyear test volume and sales forecasts
for major cancer diagnostic tests by market segment, including:
Hospitals
Commercial/Private Laboratories
Physician Offices/Group Practices
Cancer Clinics
Comprehensive market segmentation analysis, including review
of the market dynamics, structure, size, growth and major suppliers.
Cancer statistics, etiology and recent developments.
Current and Emerging Products
Review of over 200 current and emerging cancer diagnostic tests,
including:
Biochemical Markers
Oncogenes
Growth Factors
Hormones
Colony Stimulating Factors
Lymphokines
Immunohistochemical Stains, and others.
Analysis of major immunoassay analyzers used for
cancer diagnostic testing, including their operating characteristics,
features and selling prices.
Technology Review
Assessment of monoclonal antibodies, immunoassays, DNA
probes, biochips/microarrays, chromosome analysis, IT,
artificial intelligence, flow cytometry, biosensors, and other technologies
and their potential applications for cancer diagnostic testing.
Review of competing/complementing technologies, including
CT, MRI, NMR, PET and photonics spectroscopy.
Extensive listings of over 500 companies, universities
and research centers developing new cancer diagnostic tests
and detection technologies.
Competitive Assessments
Strategic assessments ofnbsp;major suppliers
and startup firms developing innovative
technologies and products, including their sales,
product portfolios, marketing tactics, collaborative
arrangements, and new products in Ramp;D.
Contains 620 pages and 103 tables
Organizations
-Indications
Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.